Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
Perspective Therapeutics has raised $175.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Perspective Therapeutics's investors include TCG Crossover, Ally Bridge Group, Commodore Capital, National Institutes of Health, Affinity Asset Advisors.
Perspective Therapeutics is headquartered in Seattle, United States.
Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
Perspective Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Perspective Therapeutics — Funding & Investors." VCBacked, February 2, 2026, https://www.vcbacked.co/company/perspective-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Perspective Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/perspective-therapeutics
{{cite web |title=Perspective Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/perspective-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated